Human Immunodeficiency Virus Clinical Trials

509 clinical trials for Human Immunodeficiency Virus across international registries, including 68 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) — RECRUITING · PHASE3
• A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) — RECRUITING · PHASE3
• Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease — RECRUITING
• Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV — RECRUITING · PHASE4
• The Trans-Led Care Study — RECRUITING · NA
• Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy — RECRUITING · PHASE1
• Nice Human Immunodeficiency Virus (HIV) Cohort — RECRUITING
• HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics — RECRUITING · NA
• A PHASE 3, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, NON-INFERIORITY, OPEN-LABEL STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CABOTEGRAVIR ULTRA LONG-ACTING PLUS RILPIVIRINE ULTRA LONG-ACTING OR CABOTEGRAVIR LONG-ACTING PLUS RILPIVIRINE LONG-ACTING IN ADULTS AND ADOLESCENTS WITH HIV WHO ARE VIROLOGICALLY SUPPRESSED ON ART — RECRUITING · PHASE3
• A PHASE 2 RANDOMIZED, ACTIVE-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AN INJECTABLE REGIMEN OF GS-3242 IN COMBINATION WITH LENACAPAVIR VERSUS BIKTARVY (BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE) IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV-1 — RECRUITING · PHASE2
• Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus — RECRUITING · PHASE2
• Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection — RECRUITING · NA
• Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study — RECRUITING · NA
• Cefixime Clinical Trial — RECRUITING · PHASE3
• HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong — RECRUITING · PHASE1
• Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care — RECRUITING · PHASE4
• Low Dose Naltrexone for Pain in Patients With HIV — RECRUITING · PHASE4
• Persuasive Health Communication Intervention for HIV/HCV — RECRUITING · NA
• Baricitinib for Reduction of HIV - CNS — RECRUITING · PHASE2
• Voluntary HIV Screening in the General Population in France — RECRUITING
• A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV — RECRUITING · PHASE4
• A PHASE 2B RANDOMIZED, OPEN-LABEL ACTIVE CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ORAL VH4524184 COADMINISTERED WITH EMTRICITABINE AND TENOFOVIR ALAFENAMIDE IN TREATMENT NAÏVE VIREMIC PERSONS WITH HIV-1 (INNOVATE STUDY) — RECRUITING · PHASE2
• Universal Test and Connect for HIV Service Delivery in South Africa — RECRUITING
• Data Science and Qualitative Research for Decision Support in the HIV Care Cascade — RECRUITING · NA
• Quitting Matters Human Immunodeficiency Virus Hybrid Trial — RECRUITING · NA
• A PHASE 2/3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL (PHASE 2) AND DOUBLE-BLIND (PHASE 3) STUDY TO EVALUATE THE ANTIRETROVIRAL ACTIVITY, SAFETY, AND TOLERABILITY OF ISLATRAVIR (ISL) AND ULONIVIRINE (ULO) ONCE WEEKLY COMPARED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (BIC/FTC/TAF) ONCE DAILY IN TREATMENT-NAÏVE ADULT PARTICIPANTS LIVING WITH HIV-1. — RECRUITING · PHASE3
• The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care — RECRUITING · NA
• Reducing Systemic Inflammation in People on Antiretroviral Therapy — RECRUITING · PHASE2
• Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults — RECRUITING · PHASE1
• Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors — RECRUITING
• Project neuroARTEMIS — RECRUITING · NA
• A PHASE 3B, OPEN LABEL, RANDOMIZED, STANDARD-OF-CARE CONTROL ARM, MULTICENTER, SUPERIORITY STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF INJECTABLE CAB LA + RPV LA IN VIREMIC PARTICIPANTS LIVING WITH HIV-1 (CROWN) — RECRUITING · PHASE3
• V+PSF-M for Tobacco Cessation in HIV Care in India — RECRUITING · PHASE3
• Text Education About Cardiovascular Health and HIV (TEACH-HIV) — RECRUITING · NA
• Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV — RECRUITING · PHASE4
• Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium — RECRUITING
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE A SWITCH TO AN ORAL WEEKLY ISLATRAVIR/LENACAPAVIR REGIMEN IN PEOPLE WITH HIV-1 WHO ARE VIROLOGICALLY SUPPRESSED ON BICTEGRAVIR/EMTRICITABINE/TENOFOVIR (B/F/TAF) — RECRUITING · PHASE3
• AN OPERATIONALLY SEAMLESS PHASE 2/3, RANDOMIZED, ACTIVE-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ORAL WEEKLY REGIMEN OF GS-1720 IN COMBINATION WITH GS-4182 VERSUS BIKTARVY IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV-1 — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TREATMENT WITH BEPIROVIRSEN IN PARTICIPANTS LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS AND CHRONIC HEPATITIS B VIRUS INFECTION ON ANTIRETROVIRAL TREATMENT — RECRUITING
• PHASE 3 DOUBLE-BLIND MULTICENTER RANDOMIZED ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BICTEGRAVIR/LENACAPAVIR VERSUS BIKTARVY® (BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE) IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV 1 — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND CLINICAL STUDY TO EVALUATE THE ANTIRETROVIRAL ACTIVITY, SAFETY, AND TOLERABILITY OF DORAVIRINE/ISLATRAVIR (DOR/ISL 100 MG/0.25 MG) ONCE-DAILY IN HIV-1 INFECTED TREATMENT-NAÏVE PARTICIPANTS — RECRUITING · PHASE3
• A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL, HYBRID TYPE I STUDY EVALUATING THE EFFICACY, SAFETY, IMPLEMENTATION EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES OF ORAL DOLUTEGRAVIR/LAMIVUDINE ONCE-DAILY AS A FIRST-LINE REGIMEN FOLLOWED BY PARTICIPANTS-DETERMINED OPTIONAL SWITCH TO LONG-ACTING INTRAMUSCULAR CABOTEGRAVIR PLUS RILPIVIRINE EVERY TWO MONTHS FOR THE MAINTENANCE OF VIROLOGIC SUPPRESSION IN ANTIRETROVIRAL THERAPY NAÏVE ADULTS LIVING WITH HIV-1 — RECRUITING · PHASE3
• A PHASE 2 STUDY OF GS-5423 AND GS-2872 IN COMBINATION WITH CAPSID INHIBITOR LENACAPAVIR IN VIROLOGICALLY SUPPRESSED ADULTS WITH HIV-1 INFECTION — RECRUITING · PHASE2
• A PHASE 3 OPEN-LABEL CLINICAL STUDY OF DORAVIRINE/ISLATRAVIR (DOR/ISL [100 MG/0.25 MG]) ONCE DAILY FOR THE TREATMENT OF HIV-1 INFECTION IN PARTICIPANTS WHO PREVIOUSLY RECEIVED DOR/ISL (100 MG/0.75 MG) QD IN A PHASE 3 CLINICAL STUDY — RECRUITING · PHASE3
• FECAL MICROBIOTA TRANSPLANTATION TO REDUCE IMMUNE ACTIVATION IN ART-TREATED PEOPLE LIVING WITH HIV WITH LOW CD4/CD8 RATIO: THE GUTSY STUDY — RECRUITING
• A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL CLINICAL STUDY TO EVALUATE A SWITCH TO DORAVIRINE/ISLATRAVIR (DOR/ISL 100 MG/0.25 MG) ONCE-DAILY IN PARTICIPANTS WITH HIV-1 WHO ARE VIROLOGICALLY SUPPRESSED ON ANTIRETROVIRAL THERAPY — RECRUITING · PHASE3
• A PHASE 3 OPEN-LABEL ROLLOVER CLINICAL STUDY OF DORAVIRINE/ISLATRAVIR (DOR/ISL) ONCE DAILY FOR THE TREATMENT OF HIV-1 INFECTION IN PARTICIPANTS WHO PREVIOUSLY RECEIVED DOR/ISL IN A PHASE 2 OR PHASE 3 DOR/ISL CLINICAL STUDY — RECRUITING · PHASE3
• ¿A PHASE 2A MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-PART ADAPTIVE DESIGN STUDY TO EVALUATE THE ANTIVIRAL EFFECT, SAFETY AND TOLERABILITY OF GSK3810109A, AN HIV-1 SPECIFIC BROADLY NEUTRALIZING HUMAN MONOCLONAL ANTIBODY IN ANTIRETROVIRAL NAÏVE HIV-1-INFECTED ADULTS.¿ — RECRUITING · PHASE2
• A PHASE 3 RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL CLINICAL STUDY TO EVALUATE A SWITCH TO DORAVIRINE/ISLATRAVIR (DOR/ISL) ONCE-DAILY IN PARTICIPANTS WITH HIV-1 VIROLOGICALLY SUPPRESSED ON ANTIRETROVIRAL THERAPY — RECRUITING · PHASE3
• CANNABINOIDS IN PEOPLE LIVING WITH HIV ON EFFECTIVE ANTIRETROVIRAL THERAPY: A PILOT STUDY TO ASSESS SAFETY, TOLERABILITY AND EFFECT ON IMMUNE ACTIVATION — RECRUITING

Refine this search